Superomniphobic flow controlled prosthetic heart valve

项目摘要： 目前所有的人工心脏瓣膜都患有并发症。机械心脏瓣膜（HV）需要终身使用 抗凝治疗，而基于固定组织的生物人工心脏瓣膜受到耐久性的困扰， 免疫原性和钙化问题。带涡流的超全憎（SO）双叶机械心脏瓣膜 发生器（VG）技术有望消除对抗凝治疗的需要。我们的实验室开发了一种 带有VG的SO双叶机械心脏瓣膜（BMHV）也可显著改善表面血液相容性 气体消除湍流应力，从而减少血小板活化。初步工作表明，SO表面 相对于普通热解碳瓣叶，血栓形成可能性显著降低。此外，我们已经 证明了制造BMHV并将其与VG组装成可植入BMHV的可行性。 本R21研究旨在评估SO BMHV与VG作为当前心脏的潜在替代方案的有效性 阀门技术通过微调材料成分和加工工艺，以满足耐久性和抗血栓形成 心脏瓣膜的要求。我们的中心假设是：具有涡流发生器流的超全憎BMHV 控制技术在血流动力学性能、血液损伤和 血液材料表面相容性，同时表现出令人满意的耐久性。这在两个目标中得到检验。要求1 量化SO与VG BMHV的心脏瓣膜血流动力学性能，以确定理想的SO + VG 配置为上级血流动力学和最小的血液损伤。目标2侧重于阐明 瓣叶组成和处理对血液相容性的影响，同时优化强度和血液相容性 的涂层。该提案由Lakshmi Prasad Dasi博士领导，他是一位训练有素的年轻研究员， 在心脏瓣膜工程和心血管生物力学方面的专业知识，以及几种心脏瓣膜的发明者 技术，包括VG和新型生物分子聚合物小叶。多PI是科塔博士，他是一个既定的 超疏水材料专家; Popat博士，其专长在于生物相容性和表面 纳米工程如果拟议的工作表明带有VG BMHV的SO会产生出色的血流动力学， 而且耐用，这项R21赠款可能会导致机械HV和所有其他血液的突破性技术， 接触器械（如人工心脏、LVAD等）几乎不需要或不需要抗凝治疗。

Project Summary: All present day prosthetic heart valves suffer from complications. Mechanical heart valves (HVs) require life-long anti-coagulation therapy, while bioprosthetic heart valves based on fixed tissue are plagued with durability, immunogenic and calcification issues. Superomniphobic (SO) bileaflet mechanical heart valves with vortex generator (VG) technology promise to eliminate the need for anti-coagulation therapy. Our lab has developed a SO bileaflet mechanical heart valve (BMHV) with VGs that drastically improve surface hemocompatibility as well as eliminate turbulent stresses, thus reducing platelet activation. Preliminary work has shown that SO surfaces remarkably reduced thrombogenic potential relative to plain pyrolytic carbon leaflets. Further, we have already demonstrated the feasibility of manufacturing BMHVs and assembling them with VGs into an implantable BMHV. The present R21 study aims to gauge the efficacy of SO BMHV with VG as a potential alternative to current heart valve technology by fine tuning material composition and processing to meet the durability and antithrombogenic requirements for heart valves. Our central hypothesis is: superomniphobic BMHVs with vortex generator flow control technology will be superior to current BMHVs in terms of hemodynamic performance, blood damage, and blood-material surface compatibility while exhibiting satisfactory durability. This is tested in two aims. Aim 1 quantifies heart valve hemodynamic performance of SO with VG BMHVs to identify the ideal SO+VG configuration for superior hemodynamics and minimum blood damage. Aim 2 focuses on elucidating the effects of leaflet composition and processing on hemocompatibility while optimizing the strength and hemocompatibility of the coating. This proposal is led by Dr. Lakshmi Prasad Dasi, who is a well trained young investigator with expertise in heart valve engineering and cardiovascular biomechanics, and inventor of several heart valve technologies including VGs and novel biomolecule polymer leaflets. Multi-PIs are Dr. Kota, who is an established superhydrophobic materials expert; Dr. Popat whose expertise lies in bio-compatibility and surface nano-engineering. If the proposed work demonstrates that SO with VG BMHVs elicit excellent hemodynamics, and are durable, this R21 grant may lead to breakthrough technology for mechanical HVs and all other blood contacting devices (e.g. artificial hearts, LVADs etc.) that require little or no anticoagulation.